

Abstract of the Disclosure

The use of low doses of IFN-gamma in the treatment of interferon-sensitive diseases is described. The IFN-gamma can be administered orally, 5 preferably buccally or sublingually, or parenterally in low doses to activate monocyte, neutrophil, or B cell function, to decrease acute inflammation, or to treat cancer, bacterial or fungal diseases, or fibrosis in a patient suffering from such disease states. Pharmaceutical formulations containing low doses of IFN-gamma in combination with a pharmaceutical acceptable carrier and suitable for oral administration are also 10 described.